Keytruda keeps expanding with another priority review; Medicxi-backed eye drop maker wins new funding, regional deal
As Merck continues to chop away at a path to earlier lines of cancer treatment for Keytruda, the FDA is offering a hand.
The agency …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
